The efficacy and safety of multiple-dose oral tranexamic acid on blood loss following total hip arthroplasty: a randomized controlled trial

Original Paper
  • 28 Downloads

Abstract

Purposes

To explore the efficacy and safety of multiple-dose oral tranexamic acid (TXA) on blood loss following primary total hip arthroplasty (THA).

Methods

A total of 152 patients were randomized into three groups to receive 2 g of oral TXA two hours  pre-operatively (group A), or another bolus of 2 g of oral TXA four hours post-operatively (group B), or another three boluses of 2 g of oral TXA four, ten, and 16 hours post-operatively (group C). The primary outcomes were total blood loss (TBL), hidden blood loss (HBL), and transfusion rate. The secondary outcomes were haemoglobin (Hb) and haematocrit (Hct) drop, the level of fibrinolysis parameters (fibrin degradation products, D-dimer), and complications (thrombotic diseases, stroke, cardiac infarction, and infection).

Results

The mean TBL and HBL in group C were lower than those in group A (p < 0.001 and p < 0.001) and group B (p = 0.012 and p = 0.029). The Hb drop on post-operative day one (POD1) and POD3 in group C was lower than those in group A (p < 0.001 and p = 0.029) and group B (p < 0.001 and p = 0.004). The difference was similar regarding Hct drop on POD3 (p < 0.001 and p = 0.014). Moreover, fibrin degradation products and D-dimer in group C were lower than in groups A and B on POD1 and POD3 (p < 0.001 and p < 0.001). The incidence of complications such as venous thromboembolism did not differ significantly among the three groups (p > 0.05).

Conclusions

Multiple boluses of oral TXA could further reduce blood loss, Hb and Hct drop, and restrain post-operative fibrinolysis in primary THA without increasing the risk of complications.

Level of Evidence I

Therapeutic study.

Keywords

Total hip arthroplasty Tranexamic acid Oral Blood loss 

Notes

Compliance with ethical standards

Conflict of interest

All authors declare no conflict of interest.

Ethical approval

The trial was approved by the institutional review board and registered at the International Clinical Trial Registry (ChiCTR-IPR-17012266).

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Hogan CA, Golightly LK, Phong S, Dayton MR, Lyda C, Barber GR (2016) Perioperative blood loss in total hip and knee arthroplasty: outcomes associated with intravenous tranexamic acid use in an academic medical center. SAGE Open Med 4:205031211663702.  https://doi.org/10.1177/2050312116637024 CrossRefGoogle Scholar
  2. 2.
    Loftus TJ, Spratling L, Stone BA, Xiao L, Jacofsky DJ (2016) A patient blood management program in prosthetic joint arthroplasty decreases blood use and improves outcomes. J Arthroplast 31(1):11–14.  https://doi.org/10.1016/j.arth.2015.07.040 CrossRefGoogle Scholar
  3. 3.
    Rajesparan K, Biant LC, Ahmad M, Field RE (2009) The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement. J Bone Joint Surg Br Vol 91(6):776–783.  https://doi.org/10.1302/0301-620x.91b6.22393 CrossRefGoogle Scholar
  4. 4.
    Xie J, Hu Q, Ma J, Huang Q, Pei F (2017) Multiple boluses of intravenous tranexamic acid to reduce hidden blood loss and the inflammatory response following enhanced-recovery primary total hip arthroplasty: a randomised clinical trial. Bone Joint J 99-b(11):1442–1449.  https://doi.org/10.1302/0301-620x.99b11.bjj-2017-0488.r1 CrossRefPubMedGoogle Scholar
  5. 5.
    Hao LQ, Wang QW, Chen WQ, Zhang ZY (2017) Comparison of oral and intravenous tranexamic acid in total knee and hip arthroplasty: a systematic review and meta-analysis. Int J Surg 47:52–53.  https://doi.org/10.1016/j.ijsu.2017.09.009 CrossRefPubMedGoogle Scholar
  6. 6.
    Imai N, Dohmae Y, Suda K, Miyasaka D, Ito T, Endo N (2012) Tranexamic acid for reduction of blood loss during total hip arthroplasty. J Arthroplast 27(10):1838–1843.  https://doi.org/10.1016/j.arth.2012.04.024 CrossRefGoogle Scholar
  7. 7.
    Lee QJ, Chang WY, Wong YC (2017) Blood-sparing efficacy of oral tranexamic acid in primary total hip arthroplasty. J Arthroplast 32(1):139–142.  https://doi.org/10.1016/j.arth.2016.06.058 CrossRefGoogle Scholar
  8. 8.
    Malhotra R, Kumar V, Garg B (2011) The use of tranexamic acid to reduce blood loss in primary cementless total hip arthroplasty. Eur J Orthop Surg Traumatol 21(2):101–104.  https://doi.org/10.1007/s00590-010-0671-z CrossRefGoogle Scholar
  9. 9.
    Yue C, Kang P, Yang P, Xie J, Pei F (2014) Topical application of tranexamic acid in primary total hip arthroplasty: a randomized double-blind controlled trial. J Arthroplast 29(12):2452–2456.  https://doi.org/10.1016/j.arth.2014.03.032 CrossRefGoogle Scholar
  10. 10.
    Kayupov E, Fillingham YA, Okroj K, Plummer DR, Moric M, Gerlinger TL, Della Valle CJ (2017) Oral and intravenous tranexamic acid are equivalent at reducing blood loss following total hip arthroplasty: a randomized controlled trial. J Bone Joint Surg Am Vol 99(5):373–378.  https://doi.org/10.2106/jbjs.16.00188 CrossRefGoogle Scholar
  11. 11.
    Luo ZY, Wang HY, Wang D, Zhou K, Pei FX, Zhou ZK (2017) Oral vs intravenous vs topical tranexamic acid in primary hip arthroplasty: a prospective, randomized, double-blind, controlled study. J Arthroplast.  https://doi.org/10.1016/j.arth.2017.09.062
  12. 12.
    Blanie A, Bellamy L, Rhayem Y, Flaujac C, Samama CM, Fontenay M, Rosencher N (2013) Duration of postoperative fibrinolysis after total hip or knee replacement: a laboratory follow-up study. Thromb Res 131(1):e6–e11.  https://doi.org/10.1016/j.thromres.2012.11.006 CrossRefPubMedGoogle Scholar
  13. 13.
    Sharrock N, Go G, Harpel PC, Ranawat CS, Sculco TP, Salvati E (1995) Thrombogenesis during total hip-arthroplasty. Clin Orthop Relat Res (319):16–27Google Scholar
  14. 14.
    Iwai T, Tsuji S, Tomita T, Sugamoto K, Hideki Y, Hamada M (2013) Repeat-dose intravenous tranexamic acid further decreases blood loss in total knee arthroplasty. Int Orthop 37(3):441–445.  https://doi.org/10.1007/s00264-013-1787-7 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Lei Y, Xie J, Xu B, Xie X, Huang Q, Pei F (2017) The efficacy and safety of multiple-dose intravenous tranexamic acid on blood loss following total knee arthroplasty: a randomized controlled trial. Int Orthop 41(10):2053–2059.  https://doi.org/10.1007/s00264-017-3519-x CrossRefPubMedGoogle Scholar
  16. 16.
    Xie J, Ma J, Yao H, Yue C, Pei F (2016) Multiple boluses of intravenous tranexamic acid to reduce hidden blood loss after primary total knee arthroplasty without tourniquet: a randomized clinical trial. J Arthroplast 31(11):2458–2464.  https://doi.org/10.1016/j.arth.2016.04.034 CrossRefGoogle Scholar
  17. 17.
    Liu X, Zhang X, Chen Y, Wang Q, Jiang Y, Zeng B (2011) Hidden blood loss after total hip arthroplasty. J Arthroplast 26(7):1100–1105.e1101.  https://doi.org/10.1016/j.arth.2010.11.013 CrossRefGoogle Scholar
  18. 18.
    Bedard NA, Pugely AJ, Lux NR, Liu SS, Gao Y, Callaghan JJ (2017) Recent trends in blood utilization after primary hip and knee arthroplasty. J Arthroplast 32(3):724–727.  https://doi.org/10.1016/j.arth.2016.09.026 CrossRefGoogle Scholar
  19. 19.
    Holt JB, Miller BJ, Callaghan JJ, Clark CR, Willenborg MD, Noiseux NO (2016) Minimizing blood transfusion in total hip and knee arthroplasty through a multimodal approach. J Arthroplast 31(2):378–382.  https://doi.org/10.1016/j.arth.2015.08.025 CrossRefGoogle Scholar
  20. 20.
    Irwin A, Khan SK, Jameson SS, Tate RC, Copeland C, Reed MR (2013) Oral versus intravenous tranexamic acid in enhanced-recovery primary total hip and knee replacement: results of 3000 procedures. Bone Joint J 95-b(11):1556–1561.  https://doi.org/10.1302/0301-620x.95b11.31055 CrossRefPubMedGoogle Scholar
  21. 21.
    Pilbrant A, Schannong M, Vessman J (1981) Pharmacokinetics and bioavailability of tranexamic acid. Eur J Clin Pharmacol 20(1):65–72CrossRefPubMedGoogle Scholar
  22. 22.
    Ralley FE, Berta D, Binns V, Howard J, Naudie DD (2010) One intraoperative dose of tranexamic acid for patients having primary hip or knee arthroplasty. Clin Orthop Relat Res 468(7):1905–1911.  https://doi.org/10.1007/s11999-009-1217-8 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Perreault RE, Fournier CA, Mattingly DA, Junghans RP, Talmo CT (2017) Oral tranexamic acid reduces transfusions in total knee arthroplasty. J Arthroplast 32(10):2990–2994.  https://doi.org/10.1016/j.arth.2017.03.063 CrossRefGoogle Scholar
  24. 24.
    Charoencholvanich K, Siriwattanasakul P (2011) Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial. Clin Orthop Relat Res 469(10):2874–2880.  https://doi.org/10.1007/s11999-011-1874-2 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Xie J, Ma J, Kang P, Zhou Z, Shen B, Yang J, Pei F (2015) Does tranexamic acid alter the risk of thromboembolism following primary total knee arthroplasty with sequential earlier anticoagulation? A large, single center, prospective cohort study of consecutive cases. Thromb Res 136(2):234–238.  https://doi.org/10.1016/j.thromres.2015.05.014 CrossRefPubMedGoogle Scholar

Copyright information

© SICOT aisbl 2018

Authors and Affiliations

  1. 1.Department of Orthopaedic Surgery, West China Hospital, West China Medical SchoolSichuan UniversityChengduPeople’s Republic of China

Personalised recommendations